Artificial exosomes for translational nanomedicine

Exosomes are lipid bilayer membrane vesicles and are emerging as competent nanocarriers for drug delivery. The clinical translation of exosomes faces many challenges such as massive production, standard isolation, drug loading, stability and quality control. In recent years, artificial exosomes are...

Full description

Saved in:
Bibliographic Details
Published inJournal of nanobiotechnology Vol. 19; no. 1; pp. 242 - 20
Main Authors Li, Yong-Jiang, Wu, Jun-Yong, Liu, Jihua, Xu, Wenjie, Qiu, Xiaohan, Huang, Si, Hu, Xiong-Bin, Xiang, Da-Xiong
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 12.08.2021
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Exosomes are lipid bilayer membrane vesicles and are emerging as competent nanocarriers for drug delivery. The clinical translation of exosomes faces many challenges such as massive production, standard isolation, drug loading, stability and quality control. In recent years, artificial exosomes are emerging based on nanobiotechnology to overcome the limitations of natural exosomes. Major types of artificial exosomes include ‘nanovesicles (NVs)’, ‘exosome-mimetic (EM)’ and ‘hybrid exosomes (HEs)’, which are obtained by top-down, bottom-up and biohybrid strategies, respectively. Artificial exosomes are powerful alternatives to natural exosomes for drug delivery. Here, we outline recent advances in artificial exosomes through nanobiotechnology and discuss their strengths, limitations and future perspectives. The development of artificial exosomes holds great values for translational nanomedicine.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1477-3155
1477-3155
DOI:10.1186/s12951-021-00986-2